|
1
|
Siegel RL, Miller KD and Jemal A: Cancer
statistics, 2017. CA Cancer J Clin. 67:7–30. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
O'Neill JP and Shaha AR: Anaplastic
thyroid cancer. Oral Oncol. 49:702–706. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Calin GA and Croce CM: MicroRNA signatures
in human cancers. Nat Rev Cancer. 6:857–866. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Bu Q, You F, Pan G, Yuan Q, Cui T, Hao L
and Zhang J: MiR-125b inhibits anaplastic thyroid cancer cell
migration and invasion by targeting PIK3CD. Biomed Pharmacother.
88:443–448. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Shao M, Geng Y, Lu P, Xi Y, Wei S, Wang L,
Fan Q and Ma W: miR-4295 promotes cell proliferation and invasion
in anaplastic thyroid carcinoma via CDKN1A. Biochem Biophys Res
Commun. 464:1309–1313. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Zhu Z, Wang S, Zhu J, Yang Q, Dong H and
Huang J: MicroRNA-544 down-regulates both Bcl6 and Stat3 to inhibit
tumor growth of human triple negative breast cancer. Biol Chem.
397:1087–1095. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Jin S, Dai Y, Li C, Fang X, Han H and Wang
D: MicroRNA-544 inhibits glioma proliferation, invasion and
migration but induces cell apoptosis by targeting PARK7. Am J
Transl Res. 8:1826–1837. 2016.PubMed/NCBI
|
|
8
|
Mao L, Zhang Y, Deng X, Mo W, Yu Y and Lu
H: Transcription factor KLF4 regulates microRNA-544 that targets
YWHAZ in cervical cancer. Am J Cancer Res. 5:1939–1953.
2015.PubMed/NCBI
|
|
9
|
Ma R, Zhang G, Wang H, Lv H, Fang F and
Kang X: Downregulation of miR-544 in tissue, but not in serum, is a
novel biomarker of malignant transformation in glioma. Oncol Lett.
4:1321–1324. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Zhi Q, Guo X, Guo L, Zhang R, Jiang J, Ji
J, Zhang J, Zhang J, Chen X, Cai Q, et al: Oncogenic miR-544 is an
important molecular target in gastric cancer. Anticancer Agents Med
Chem. 13:270–275. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Livak KJ and Schmittgen TD: Analysis of
relative gene expression data using real-time quantitative PCR and
the 2(-Delta Delta C(T)) method. Methods. 25:402–408. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Agarwal V, Bell GW, Nam JW and Bartel DP:
Predicting effective microRNA target sites in mammalian mRNAs.
Elife. (4)2015.
|
|
13
|
Brabletz T, Kalluri R, Nieto MA and
Weinberg RA: EMT in cancer. Nat Rev Cancer. 18:128–134. 2018.
View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Shi Y, Seto E, Chang LS and Shenk T:
Transcriptional repression by YY1, a human GLI-Kruppel-related
protein and relief of repression by adenovirus E1A protein. Cell.
67:377–388. 1991. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Gordon S, Akopyan G, Garban H and Bonavida
B: Transcription factor YY1: Structure, function, and therapeutic
implications in cancer biology. Oncogene. 25:1125–1142. 2006.
View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Bonavida B and Kaufhold S: Prognostic
significance of YY1 protein expression and mRNA levels by
bioinformatics analysis in human cancers: A therapeutic target.
Pharmacol Ther. 150:149–168. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Seligson D, Horvath S, Huerta-Yepez S,
Hanna S, Garban H, Roberts A, Shi T, Liu X, Chia D, Goodglick L and
Bonavida B: Expression of transcription factor Yin Yang 1 in
prostate cancer. Int J Oncol. 27:131–141. 2005.PubMed/NCBI
|
|
18
|
Kang W, Tong JH, Chan AW, Zhao J, Dong Y,
Wang S, Yang W, Sin FM, Ng SS, Yu J, et al: Yin Yang 1 contributes
to gastric carcinogenesis and its nuclear expression correlates
with shorter survival in patients with early stage gastric
adenocarcinoma. J Transl Med. 12:802014. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Allouche A, Nolens G, Tancredi A,
Delacroix L, Mardaga J, Fridman V, Winkler R, Boniver J, Delvenne P
and Begon DY: The combined immunodetection of AP-2alpha and YY1
transcription factors is associated with ERBB2 gene overexpression
in primary breast tumors. Breast Cancer Res. 10:R92008. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Chinnappan D, Xiao D, Ratnasari A, Andry
C, King TC and Weber HC: Transcription factor YY1 expression in
human gastrointestinal cancer cells. Int J Oncol. 34:1417–1423.
2009.PubMed/NCBI
|
|
21
|
Qu SY, Sun YY, Li YH, Xu ZM and Fu WN: YY1
directly suppresses MYCT1 leading to laryngeal tumorigenesis and
progress. Cancer Med. 6:1389–1398. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Liu D, Zhang J, Wu Y, Shi G, Yuan H, Lu Z,
Zhu Q, Wu P, Lu C, Guo F, et al: YY1 suppresses proliferation and
migration of pancreatic ductal adenocarcinoma by regulating the
CDKN3/MdM2/P53/P21 signaling pathway. Int J Cancer. 142:1392–1404.
2018. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Arribas J, Castellví J, Marcos R, Zafón C
and Velázquez A: Expression of YY1 in differentiated thyroid
cancer. Endocr Pathol. 26:111–118. 2015. View Article : Google Scholar : PubMed/NCBI
|
